Alefacept - Astellas Pharma
Alternative Names: Amevive; ASP 0485; BG 9273; BG 9712; Human LFA-3/IgG fusion protein; LFA 3 TIP; Recombinant LFA-3/IgG1 human fusion proteinLatest Information Update: 05 Nov 2023
At a glance
- Originator University of Michigan Medical School
- Developer Astellas Pharma; Cleveland Clinic
- Class Antipsoriatics; Recombinant fusion proteins
- Mechanism of Action CD2 antigen inhibitors; Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Psoriasis
- No development reported Aplastic anaemia
- Discontinued Psoriatic arthritis; Transplant rejection
Most Recent Events
- 08 Apr 2021 No development reported - Phase-I/II for Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
- 24 Jan 2018 Astellas Pharma terminates a phase I/II trial due to the study drug not available at the time in Aplastic anaemia (Treatment-experienced) in USA (IV) (NCT01267643)
- 15 Mar 2012 Astellas Pharma completes its Phase-II trial for Psoriasis in USA, Bulgaria and Latvia (NCT00808223)